Jul 2026· Australian and New Zealand journal of psychiatry (Print)· pp.
48674261461986
· 1 citation· 61 references
Medicine
TL;DR
This commentary explores the complex overlaps among shared histories, risk factors and symptomatology, as well as the difficulties stemming from the absence of validated assessment tools to aid in diagnostic clarification, in the context of early psychosis.
Abstract
The Australian and New Zealand Journal of Psychiatry GRADE Evidence Guidelines for Schizophrenia highlight the importance of considering psychiatric comorbidities, including autism spectrum disorder. These guidelines acknowledge that there is limited empirical research to guide the management of individuals with schizophrenia who also have these comorbid conditions. This lack of evidence poses challenges for clinicians, especially those working in early psychosis services, where the possibility of a missed diagnosis of autism spectrum disorder is increasingly being examined, and pre-existing diagnoses of autism spectrum disorder are not uncommon. This commentary explores the complex overlaps among shared histories, risk factors and symptomatology, as well as the difficulties stemming from the absence of validated assessment tools to aid in diagnostic clarification. Psychotic symptoms may complicate the recognition and differentiation of underlying neurodevelopmental characteristics of autism spectrum disorder. Considering the limited available evidence, practical guidance is offered to assist clinicians in their decision-making when a strong evidence base is lacking. In the context of early psychosis, diagnostic formulation should be considered provisional, with assessment of a possible a missed ASD diagnosis occurring after the stabilisation of psychotic symptoms wherever possible.
A narrative review of papers published between 1 January 2015 and 16 February 2026 that were pertinent to comorbidity and autism finds how the variable risk of comorbidity mimics the heterogeneity present in autism, thus inviting further investigations.
E. Dando, Juergen Hahn, D. Geier et al.· Healthcare· 0 citations
This review systematically summarizes the conceptual definition and clinical phenotypes of profound autism and emphasizes the need to shift the intervention focus toward managing serious comorbidities and establishing augmentative and alternative communication systems.
Yang Xue, Fei-yong Jia· Zhongguo dang dai er ke za z...· 0 citations
The latest diagnostic criteria according to DSM-5 2013 is very helpful in terms of treating autism as spectrum of different abilities and allow for designing a bespoke individualised interventional approaches to help people with autism.
A. SalimaY., A. ElzoukiOsama, Tashani· 0 citations
Abstract Purpose Negative symptoms remain a primary driver of functional disability in schizophrenia spectrum disorders. This article presents the official Danish Multidisciplinary Psychiatry Group’s (DMPG) national clinical guideline for the assessment and treatment of negative symptoms in psychotic disorders across the lifespan. Materials and methods A systematic literature search for systematic reviews and meta-analyses published between 2019 and 2024 was conducted in PubMed and PsycInfo. Studies were screened and extracted by independent reviewers using Covidence. To ensure clinical utility, recommendations were formulated by synthesizing the evidence base with expert consensus, which included extrapolating adult data to formulate guidance for children and adolescents where primary evidence is scarce. Results The consensus process yielded 21 specific clinical recommendations. The guideline mandates the assessment of five distinct domains (anhedonia, asociality, alogia, avolition, and blunted affect) using dedicated scales like the BNSS. It provides clear guidance on pharmacological strategies, including a conditional endorsement of modafinil augmentation and a recommendation against cannabinoids. Evidence-based psychosocial interventions, such as cognitive behavioral therapy and cognitive remediation, are also recommended. Conclusions The guideline establishes a comprehensive, clinically actionable framework for managing negative symptoms in children, adolescents, and adults. Furthermore, it emphasizes that advancing the field requires future research to utilize domain-specific tools to accurately distinguish primary from secondary negative symptoms.
Sofie Norlin Mølgaard, L. Glenthøj, R. Arendt et al.· Nordic Journal of Psychiatry· 0 citations
There is an urgent need for prospective longitudinal studies to adequately map the aging trajectories of this population of older adults with ASD, which constitute a vulnerable population.
J. P. S. Gontijo, Marcelo H S S Martins, L. M. Alves· Trends in Psychiatry and Psy...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.